Unravelling the mechanotransduction pathways in Alzheimer’s disease

被引:0
|
作者
Francesca Donnaloja
Emma Limonta
Christian Mancosu
Francesco Morandi
Lucia Boeri
Diego Albani
Manuela Teresa Raimondi
机构
[1] Materials and Chemical Engineering “G. Natta”,Politecnico Di Milano, Department of Chemistry
[2] Istituto di Ricerche Farmacologiche Mario Negri IRCCS,Department of Neuroscience
关键词
Nuclear lamina; Alzheimer’s disease; Extracellular matrix; Nuclear-cytoplasmic transport; Tau; Synaptic loss;
D O I
暂无
中图分类号
学科分类号
摘要
Alzheimer’s disease (AD) represents one of the most common and debilitating neurodegenerative disorders. By the end of 2040, AD patients might reach 11.2 million in the USA, around 70% higher than 2022, with severe consequences on the society. As now, we still need research to find effective methods to treat AD. Most studies focused on the tau and amyloid hypothesis, but many other factors are likely involved in the pathophysiology of AD. In this review, we summarize scientific evidence dealing with the mechanotransduction players in AD to highlight the most relevant mechano-responsive elements that play a role in AD pathophysiology. We focused on the AD-related role of extracellular matrix (ECM), nuclear lamina, nuclear transport and synaptic activity. The literature supports that ECM alteration causes the lamin A increment in the AD patients, leading to the formation of nuclear blebs and invaginations. Nuclear blebs have consequences on the nuclear pore complexes, impairing nucleo-cytoplasmic transport. This may result in tau hyperphosphorylation and its consequent self-aggregation in tangles, which impairs the neurotransmitters transport. It all exacerbates in synaptic transmission impairment, leading to the characteristic AD patient’s memory loss. Here we related for the first time all the evidence associating the mechanotransduction pathway with neurons. In addition, we highlighted the entire pathway influencing neurodegenerative diseases, paving the way for new research perspectives in the context of AD and related pathologies.
引用
收藏
相关论文
共 50 条
  • [21] Antioxidant Pathways in Alzheimer's Disease: Possibilities of Intervention
    Vina, J.
    LLoret, A.
    Giraldo, E.
    Badia, M. C.
    Alonso, M. D.
    CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (35) : 3861 - 3864
  • [22] Mitochondrial Regulatory Pathways in the Pathogenesis of Alzheimer's Disease
    Adiele, Reginald C.
    Adiele, Chiedukam A.
    JOURNAL OF ALZHEIMERS DISEASE, 2016, 53 (04) : 1257 - 1270
  • [23] New pathways in drug discovery for Alzheimer's disease
    Siemers, Eric R.
    Dean, Robert A.
    Demattos, Ronald
    May, Patrick C.
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2006, 6 (05) : 372 - 378
  • [24] Pathways towards and away from Alzheimer's disease
    Mark P. Mattson
    Nature, 2004, 430 : 631 - 639
  • [25] Oxidative signalling and inflammatory pathways in Alzheimer's disease
    Anderson, I
    Adinolfi, C
    Doctrow, S
    Huffman, K
    Joy, KA
    Malfroy, B
    Soden, P
    Rupniak, HT
    Barnes, JC
    NEURONAL SIGNAL TRANSDUCTION AND ALZHEIMER'S DISEASE, 2001, 67 : 141 - 149
  • [26] Proteomic Insight Into Alzheimer's Disease Pathogenesis Pathways
    Ryu, Taekyung
    Kim, Kyungdo
    Asiimwe, Nicholas
    Na, Chan Hyun
    PROTEOMICS, 2025,
  • [27] On the horizon: pathways for drug development in Alzheimer's disease
    Hake, AM
    Farlow, MR
    CLINICS IN GERIATRIC MEDICINE, 2004, 20 (01) : 141 - +
  • [28] The person with Alzheimer's disease: Pathways to understanding the experience
    Levy-Storms, L
    GERONTOLOGIST, 2005, 45 (01): : 135 - 139
  • [29] Lipid metabolism and Alzheimer's disease: pathways and possibilities
    Saxena, Uday
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2009, 13 (03) : 331 - 338
  • [30] Pathways towards and away from Alzheimer's disease
    Mattson, MP
    NATURE, 2004, 430 (7000) : 631 - 639